A pharmaceutical company launched a Phase I/II study on a novel drug for treating infected diabetic foot ulcers (DFU). After one year of recruitment, only 12 of 26 needed subjects were enrolled. The recruitment deadline was quickly approaching.
Study
nRollmed designed an awareness campaign using print and digital advertising. Leads were pre-screened to ensure only highly qualified patients were referred to the sites.
Strategy
nRollmed worked within the sponsor’s budget and provided 260 leads. After pre-screening, 70 patients were referred to sites, 6 of whom signed consent. 4 of these were randomized, with a 33% screen fail rate, improving on the sponsor’s expected screen fail rate of 60-75%.
Results
260
leads in 2 months
6
signed consent
3x
the monthly recruitment rate
nRollmed’s referrals equal more than 50% of enrollments
